Clinical Trial Update: Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update reporting safety and tolerability of intravenous MB07133 in patients with unresectable hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• MB07133

Snippet

Sponsor: Ligand Pharmaceuticals | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: COMPLETED